2. How is the economic assessment of vaccines performed today?

References

• Standaert B, Rappuoli R. The building blocks for a health economic assessment of vaccination. J Mark Access Health Policy. 2017;5:1335162.
   Google Scholar
• Postma MJ, Standaert BA. Economics of vaccines revisited. Hum Vaccin Immunother. 2013;9(5):1–14.
   Web of Science ®Google Scholar
• Ricciardi W, Toumi M. National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning. J Mark Access Health Policy. 2015;3: 29276.
   Google Scholar
• Marsh K, Phillips CJ, Fordham R, et al. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods. Health Econ Rev. 2012;2(1):17.
   Google Scholar
• Bärnighausen T, Berkley S. Reassessing the value of vaccines. Lancet. 2014;2(5):e251–e252.
   Web of Science ®Google Scholar
• Jit M, Hutubessy R, Png ME, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy. 2016;14(3):245–252.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European Vaccine Economics Community. Pharmacoeconomics. 2016;34(3):227–244.
   PubMed Web of Science ®Google Scholar
• Sloan F. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. 1st ed. Cambridge: Cambridge University Press; 1995.
   Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• Lopalco PL, de Carvalho HG, Kreidl P, et al. Childhood vaccination schedules in Europe vary widely. Is this a problem? Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009;52(11):1095–1098.
   PubMed Web of Science ®Google Scholar
• Standaert B. Are changes occurring in the perceived value of vaccines? Belgian J Pediatr. 2016;18(4):325–327.
   Google Scholar
• Standaert B, Strens D, Li X, et al. The sustained rotavirus vaccination impact on nosocomial infection, duration of hospital stay, and age: the RotaBIS study (2005–2012). Infect Dis Ther. 2016;5(4):509–524.
   PubMed Web of Science ®Google Scholar
• Martin A, Cottrell S, Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ. 2008;11(3):471–484.
   PubMedGoogle Scholar
• Sussman AL, Helitzer D, Bennett A, et al. Catching up with the HPV vaccine: challenges and opportunities in primary care. Ann Fam Med. 2015;13(4):354–360.
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22.
   PubMed Web of Science ®Google Scholar
• Zipprich J, Winter K, Hacker J, et al. Measles outbreak–California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64(6):153–154.
   PubMed Web of Science ®Google Scholar
• Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26(Suppl 5):F46–F58.
   Google Scholar
• Standaert B, Strens D, Alwan A, et al. Medium- to long-term impact of rotavirus vaccination on hospital care in Belgium: a 7-year follow-up of the Rotavirus Belgium Impact Study (RotaBIS). Infect Dis Ther. 2016;5(1):31–44.
   PubMed Web of Science ®Google Scholar
• Farrington CP. Estimation of vaccine effectiveness using the screening method 1. Int J Epidemiol. 1993;22(4):742–746.
   PubMed Web of Science ®Google Scholar
• Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76(Suppl 2):22–25.
   PubMedGoogle Scholar
• Heymann DL, Aylward RB. Eradicating polio. N Engl J Med. 2004;351(13):1275–1277.
   Web of Science ®Google Scholar
• Lee Ventola C. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277–283.
   Google Scholar
• Standaert B, Curran D, Postma J. Budget constraint and vaccine dosing: a mathematical modelling exercise. Cost Eff Resour Alloc. 2014;12(1):3.
   Web of Science ®Google Scholar
• Bala MV, Zarkin GA, Mauskopf JA. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses. Value Health. 2002;5(4):338–346.
   Web of Science ®Google Scholar
• Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015;5:23.
   Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–3794.
   Web of Science ®Google Scholar
• Dasgupta P. Economics, a very short introduction. Oxford: Oxford University Press; 2007.
   Google Scholar
• Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15(2):265–302.
   PubMed Web of Science ®Google Scholar
• Scarbrough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother. 2015;11(9):2142–2157.
   PubMed Web of Science ®Google Scholar
• Thomas SL, Walker JL, Fenty J, et al. Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted. Vaccine. 2016;35(4):680–686.
   Web of Science ®Google Scholar
• Weisberg E, Bateson D, McCaffery K, et al. HPV vaccination catch up program - utilisation by young Australian women. Aust Fam Physician. 2009;38(1–2):72–76.
   PubMed Web of Science ®Google Scholar
• Standaert B, Alwan A, Strens D, et al. Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: an evaluation study in Belgium. Hum Vaccin Immunother. 2015;11(9):2266–2273.
   PubMed Web of Science ®Google Scholar
• Standaert B, Li X, Strens D, et al. Cost analysis of two methods for improving the Quality of Care (Qoc) scores in paediatric hospital wards during winter periods. Value Health. 2015;18(7):A596–A597.
   Web of Science ®Google Scholar
• Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program for the USA. JAMA. 1998;279(17):1371–1376.
   Web of Science ®Google Scholar
• Standaert B, Van de Mieroop E, Nelen V. Exploring the potential impact of rotavirus vaccination on work absenteeism among female administrative personnel of the City of Antwerp through a retrospective database analysis. BMJ Open. 2015;5(6):e007453.
   PubMed Web of Science ®Google Scholar
• Gillick MR, Serrell NA, Gillick LS. Adverse consequences of hospitalization in the elderly. Soc Sci Med. 1982;16(10):1033–1038.
   PubMed Web of Science ®Google Scholar
• Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine. 2007;25(32):5945–5957.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Picazo JJ, Remy V. The intangible benefits of vaccination – what is the true economic value of vaccination? J Mark Access Health Policy. 2015;3: 26964.
   Google Scholar
• Oteng B, Marra F, Lynd LD, et al. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. Sex Transm Infect. 2011;87(1):52–57.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Topachevskyi O, Standaert B, et al. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics. 2012;30(8):681–695.
   Web of Science ®Google Scholar
• Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002;415(6872):680–685.
   PubMed Web of Science ®Google Scholar
• Bloom D, Canning D. Epidemics and economics. Boston: Harvard School of Public Health; 2006. (PGDA Working paper No 9).
   Google Scholar
• Drummond M, Sculpher M, Torrance G, et al. Cost-utility analysis. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 137–210.
   Google Scholar
• Verguet S, Kim JJ, Jamison DT. Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics. 2016;34(9):913–923.
   PubMed Web of Science ®Google Scholar
• Barnighausen T, Bloom DE, Canning D, et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine 2. Vaccine. 2011;29(13):2371–2380.
   Web of Science ®Google Scholar
• Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998;13(3):277–288.
   PubMed Web of Science ®Google Scholar
• Topachevskyi O, Standaert B, Van Bellinghen L, et al. Can a Multi-Criteria Decision (MCD) optimisation model help decision makers in the optimal selection of vaccines when expanding their universal mass vaccination programme? The case of Poland. Value Health. 2013;16(7):A615.
   Web of Science ®Google Scholar
• Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30(4):337–353.
   Web of Science ®Google Scholar
• Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003;21(12):839–851.
   Web of Science ®Google Scholar
• Kotsopoulos N, Connolly MP, Postma MJ, et al. Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation 1. Vaccine. 2013;31(46):5430–5434.
   PubMed Web of Science ®Google Scholar
• Somi MF, Butler JR, Vahid F, et al. Economic burden of malaria in rural Tanzania: variations by socioeconomic status and season. Trop Med Int Health. 2007;12(10):1139–1147.
   Web of Science ®Google Scholar
• Worrall E, Basu S, Hanson K. Is malaria a disease of poverty? A review of the literature. Trop Med Int Health. 2005;10(10):1047–1059.
   PubMed Web of Science ®Google Scholar
• Su T, Kouyate B, Flessa S. Catastrophic household expenditure for health care in a low-income society: a study from Nouna District, Burkina Faso. Bull World Health Organ. 2006;84(1):21–27.
   PubMed Web of Science ®Google Scholar
• Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
   PubMed Web of Science ®Google Scholar
• Milne RJ, Grimwood K. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value Health. 2009;12(6):888–898.
   PubMed Web of Science ®Google Scholar
• Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J. 2008;27(1):S20–S27.
   Web of Science ®Google Scholar
• Kim LG, Thompson SG. Uncertainty and validation of health economic decision models. Health Econ. 2010;19(1):43–55.
   Web of Science ®Google Scholar
• Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM modeling good research practices task force–5. Value Health. 2012;15(6):828–834.
   PubMed Web of Science ®Google Scholar
• Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force–7. Value Health. 2012;15(6):843–850.
   PubMed Web of Science ®Google Scholar
• Hohne JM, Demarteau N, Saka O, et al. How do decision makers in Europe value other economic evaluation tools than cost-effectiveness analysis for vaccines? Value Health. 2014;17(7):A675–A676.
   Web of Science ®Google Scholar
• Hurley J. An overview of the normative economics of the health sector. In: Cuyler A, Newhouse J, editors. Handbook of health economics (1A). 1st ed. Amsterdam: Elsevier Science; 2000. p. 56–118.
   Google Scholar